Huiqiang Huang

5PUBLICATIONS
44CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

|Mar 28, 2026
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

Yuchen Zhang, Man Nie, Yi Cao

|Oct 15, 2025
Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma.

Cheng Huang, Yan Gao, Jianfeng Chen

|Apr 29, 2025
Reply to "Concerns regarding stem cell mobilization in liposomal mitoxantrone therapy for relapsed/refractory T-cell/natural killer-cell lymphomas".

Yan Gao, Hui-Qiang Huang

|Feb 06, 2025
High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study.

Yan Gao, Liqin Ping, Changguo Shan

Pageof 1

Frequent Collaborators

3 joint publications

Yan Gao

2 joint publications

Zhiming Li

2 joint publications

Qingqing Cai

2 joint publications

Yi Xia